Clinical Trials · NCT02223416

A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo

CompletedPhase 1Teriparatide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Gedeon Richter Plc.
Enrollment
0
Start date
Not specified
Locations
1 site, United Kingdom
Primary endpoint
Area under the plasma concentration versus time curve (AUC)
View Teriparatide compound reference